Duke CFAR Funding Opportunities

amfAR aims to support research projects focused on curing HIV.

If you are an HIV researcher holding a doctoral degree and affiliated with a nonprofit research institute, tell us:

  • what you’d like to do
  • why
  • how much it will cost, and
  • how long it will take

If it’s an idea we think might be right for us, we’ll be in touch to start talking through more specifics and, if we can find a mutually satisfactory study design, solicit a full proposal.

You can submit queries at any time. Full proposals will be reviewed each February, May and August, with funding to start in March, June and September.

Our priority is to fund biomedical research that aims to achieve an eradicative HIV cure.

Send your brief synopsis (see instructions below) to grants@amfar.org with the subject line, “Target Grants – Synopsis.” We regret we are unable to discuss every submission with applicants.

Details

Background and Purpose

amfAR’s research initiatives are aimed at finding a cure for HIV that will be useful to the 38M people living with HIV. The urgency of our goal demands that we direct our funding to studies that uncover vital knowledge directly applicable to curing HIV.

Persistent reservoirs of virus not cleared by antiretroviral therapy (ART) represent the main barrier to a cure. amfAR prioritizes the development of an eradicative cure over ART-free control of persistent virus. Eradication is preferred by PWH, should obviate the need for ongoing monitoring, may result in seroreversion with its attendant benefits, and is an unambiguous improvement over treatment, including with long-acting ART. However, amfAR also recognizes the value of a cure by ART-free control of persisting virus.

An eradicative cure requires the removal of HIV proviruses, or the cells that harbor them. Although not strictly necessary, an eradicative cure that also protects individuals from reinfection is of particularly high interest.

The development of a cure will require a series of well-planned research steps. The development pipeline is commonly thought to proceed from in vitro through ex vivo and preclinical animal testing stages before proceeding to clinical trial. Applicants should be able to:

  • describe the clinical intervention they are working towards;
  • articulate the current stage of development of their product; and
  • describe the steps needed to progress to clinical testing.

Applicants may propose laboratory, animal or clinical research. Applicants should articulate a series of milestones that culminate in a clinical trial of the cure concept under consideration. Applications must be interventional, not descriptive.

Download this document and fill in the appropriate details. When completed please email it to grants@amfar.org. Incomplete submissions will not be considered further.

  • Participating Organization(s) and Components: National Institutes of Health (NIH), Fogarty International Center (FIC), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Cancer Institute (NCI)
  • Purpose: The goals of this program are to support locally relevant research in critical areas of HIV-associated non-communicable diseases (NCDs) at Low- and Middle-Income Country (LMIC) Institutions, to enhance research capacity, and to build a network of researchers both within and across LMICs to address this critical burden. This initiative is expected to stimulate new research on the interplay between HIV and development of NCDs in persons living with HIV (PLWH). This includes exploratory studies to uncover the extent to which HIV infection influences the etiopathogenesis of the NCDs; and to identify and develop appropriate approaches for effective diagnosis, prevention, therapeutic interventions and integrated clinical care for PLWH with the comorbid conditions. Applicants should develop their studies in keeping with the NIH HIV/AIDS Research Priorities

    (https://www.oar.nih.gov/hiv-policy-and-research/research-priorities ;

    https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-018.html) .  Research teams should contain an appropriate mix of expertise to accomplish the proposed studies, including partnerships between HIV and NCD researchers who can initiate new ideas and determine feasibility of novel approaches to understand and reduce the long-term suffering from the comorbid disorders. Applicants will also be asked to address the needs of collaborating LMIC institutions to develop capacity for carrying out research in this field.

  • Open Date: November 8, 2021
  • Amount of Award: The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $150,000 may be requested in any single year. The budget request must reflect the actual needs of the proposed project.
  • Due Date: Please see NIH posting for detailed information
  • More Information: NIH
  • Expiration Date: December 9, 2022
  • Participating Organization(s) and Components: National Institutes of Health (NIH), National Institute on Deafness and Other Communication Disorders (NIDCD)
  • Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to stimulate HIV/AIDS research within the scientific mission areas of the National Institute on Deafness and Other Communications Disorders (NIDCD). Applications should address high priority HIV/AIDS research outlined by the NIH Office of AIDS Research (OAR) [https://www.oar.nih.gov/hiv-policy-and-research/research-priorities] in the areas of hearing, balance, taste, smell, voice, speech, and language.

    For applications with a clinical trial, only low risk clinical trials will be supported.

  • Open Date: April 7, 2020
  • Amount of Award: Application budgets are limited to no more than $499,999 in direct costs in any year and need to reflect the actual needs of the proposed project.
  • Due Date:Standard AIDS dates apply.
    All applications are due by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on the listed date(s).
    Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  • More Information: NIH
  • Expiration Date: January 8, 2023
  • Participating Organization(s) and Components: National Institutes of Health (NIH), National Institute on Deafness and Other Communication Disorders (NIDCD)
  • Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to stimulate HIV/AIDS research within the scientific mission areas of the National Institute on Deafness and Other Communications Disorders (NIDCD). Applications should address high priority HIV/AIDS research outlined by the NIH Office of AIDS Research (OAR) [https://www.oar.nih.gov/hiv-policy-and-research/research-priorities] in the areas of hearing, balance, taste, smell, voice, speech, and language.

    For applications with a clinical trial, only low risk clinical trials will be supported.

  • Open Date: April 7, 2020
  • Amount of Award: The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year.
  • Due Date:Standard AIDS dates apply.
    All applications are due by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on the listed date(s).
    Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  • More Information: NIH
  • Expiration Date: January 8, 2023

The NIH has opened the 2021 Adelante RFA.

Adelante - meaning forward or onward in Spanish – is funded by the NIH/NIMHD and administered through two NIH-funded Center for AIDS Research (CFARs): District of Columbia and Emory University. Through this program, the NIH strives to promote the mentored development of early-career investigators who focus on HIV/AIDS prevention, treatment, and care in Latinx communities.

The Adelante program supports 2-year Adelante Teams consisting of a scholar (Early Stage Investigator), a CFAR affiliated mentor, and a collaborating partner who is a representative from a Community-based Organization that serves Latinx populations. Adelante teams should be supportive and interdisciplinary. Proposed research should be community-based and reflect local Hispanic/Latinx-community needs, as identified by science and the local community. Research proposal topics may include but are not limited to: 

  • Developing, testing, and implementing strategies to improve HIV testing and entry into prevention services by Latinx/Hispanic people.
  • Long-term prevention strategies specific to Latinx populations for HIV-relevant coinfections and comorbid conditions across the lifespan
  • Effective socio-behavioral interventions to achieve uptake of HIV prevention and treatment strategies by Latino/Hispanic people and reduce health disparities among Latinx populations.
  • Implementation research tailored specifically for Latinx populations that is designed to ensure that biomedical and other prevention and treatment strategies are initiated as soon as possible, that retention and engagement in treatment services is increased, and/or that maintenance of optimal prevention and treatment responses are achieved.
  • Research that examines HIV-related health and social issues in Latinx populations, such as other infectious or non-infectious conditions and substance use or mental health disorders that are clearly linked with HIV (transmission/acquisition, pathogenesis, morbidity and mortality, stigma) in sub-populations or settings with high HIV prevalence or incidence.

Applicants may request up to $100,000 in direct costs per year ($200,000 over two years) plus applicable indirect costs, not to exceed direct costs per year. This funding may be used for salaries, technical support, laboratory supplies, equipment, and for research- or training-related activities including but not limited to enrollment in training classes or workshops, travel to the CFAR Mentor's institution, or travel to the research field site.

You can find the Adelante Fact Sheet here and more information about the program including the full RFA at the Adelante website here.

  • Participating Organization(s) and Components: National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
  • Purpose:The purpose of this FOA is to support the testing of enhanced models of care that optimally integrate HIV, addiction, and primary care services.  NIDA is interested in research that addresses gaps related to the delivery of comprehensive, integrated health services to include the full continuum of HIV/AIDS services, addiction prevention and treatment services, and primary care services, with a goal of improving the coordination of care, and improving health outcomes related to HIV and SUD in the US.
  • Open Date: August 28, 2020
  • Amount of Award: Application budgets are not limited but need to reflect the actual needs of the proposed project.
  • Due Date: November 18, 2020, August 11, 2021, November 18, 2021, August 11, 2022, November 18, 2022, August 11, 2023
  • More Information: NIH
  • Expiration Date: August 12, 2023
  • Issued By: National Institute of Mental Health (NIMH)
  • Purpose: The National Institute of Mental Health is issuing this Notice to highlight interest in research applications to optimize health communication strategies that advance HIV prevention, treatment and cure.
  • Release Date: March 2, 2021
  • More Information: NIH
  • Expiration Date: May 9, 2024
  • Issued By: National Institute on Drug Abuse (NIDA)
  • Purpose: The purpose of this Notice is to encourage grant applications proposing research that makes use of available, large data sets with the objective of improving HIV epidemic modeling and service planning, with greater attention to the role of substance use. Data may be from NIDA-funded or co-funded projects as well as from other sources. This Notice is expected to increase the utilization of existing data including epidemiologic and clinic cohorts, longitudinal follow-up studies of interventions, as well as other publicly available data including those provided by government bodies, data warehouses and commercial data sources. Existing data may include data from completed projects as well as those that are ongoing.

    Results from studies supported by this NOSI are expected to generate knowledge that can be used to answer significant questions about HIV epidemics, promote efficient provision of services, and address limitations of existing models that have guided public policy. NIDA is particularly interested in research that integrates substance use considerations into program planning and policy to increase the quality of HIV services and their responsiveness to substance using populations.

  • Release Date: February 26, 2021
  • More Information: NIH
  • Expiration Date: September 8, 2024